Search Results
Your search for ,WHo matches 20204 pages
Showing 15751 - 15800Similar 15-year Functional Outcomes after Prostatectomy or Radiotherapy for Localized Prostate Cancer
Comparative longer-term functional outcomes of radical prostatectomy and external-beam radiation therapy for localized prostate cancer remain undefined. In a study recently reported in The New England Journal of Medicine,1 Matthew J. Resnick, MD, and colleagues at Vanderbilt University, Nashville,...
FDA Approves New Radioactive Diagnostic Imaging Agent to Help Locate Lymph Nodes in Patients with Certain Cancers
The FDA has approved technetium Tc 99m tilmanocept (Lymphoseek Injection), a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes. Tilmanocept is an imaging drug that...
BRAF Mutations in Colorectal Cancer: The Next Frontier
Some 5% to 10% of patients with colorectal cancer harbor the BRAF mutation, placing them at risk for poor treatment response and worse outcomes. The ASCO Post interviewed S. Gail Eckhardt, MD, an expert in this area who is Professor and Head of the Division of Medical Oncology at the University of...
Society of Surgical Oncology Fellow Receives Colorectal Cancer Research Scholar Award
The Colon Cancer Challenge Foundation (CCCF) and the Society of Surgical Oncology (SSO) named Karen Lo, MD, a surgical resident at the University of Colorado, as recipient of third annual Colorectal Cancer Research Scholar Award. The award was presented at the SSO Annual Cancer Symposium held...
Important Data and Treatment Advances Reported in GIST and in Pancreatic and Liver Cancers
The 10th annual Gastrointestinal Cancers Symposium, held recently in San Francisco, was jointly sponsored by ASCO, the AGA (American Gastroenterological Association), ASTRO (American Society for Radiation Oncology), and the SSO (Society of Surgical Oncology). “We seek to present the newest...
Clinical-Pathologic Stage Discrepancy High in Patients with Bladder Cancer Undergoing Surgery
About 48% of all patients with bladder cancer undergoing radical cystectomy have a discrepancy between their clinical stage and pathologic stage, according to the largest study to date to examine this issue. Upstaging after surgery is associated with reduced survival, while downstaging after...
New Findings in Prostate and Kidney Cancers Clarify the Roles of Abiraterone, Finasteride, Bevacizumab, and Surveillance
Attendees at the 2013 Genitourinary Cancers Symposium in Orlando, Florida, were brought up to date with the latest news on cancers of the prostate, testes, bladder, and kidney. Below are selected highlights from the meeting describing findings of noteworthy abstracts to extend our regular news...
Errata
In the March 1 issue of The ASCO Post, the article on page 2, “Outcomes Comparable for Panitumumab and Bevacizumab in Metastatic Colorectal Cancer,” contained an inaccuracy about the FDA-approved indications of bevacizumab (Avastin) in colorectal cancer. Specifically, the article noted that...
Homoharringtonine/Omacetaxine: The Little Drug that Could
First, a clarification: Homoharringtonine is a natural plant alkaloid derived from Cephalotaxus fortunei; from the 1970s until the present, it was the subject of intensive research efforts by Chinese investigators to clarify its role as an antileukemic agent.1-3 Omacetaxine mepesuccinate (Synribo)...
Sexual Health after Cancer: Communicating with Your Patients
Studies show virtually all cancer survivors will experience some form of sexual dysfunction following a cancer diagnosis and treatment. Yet few cancer survivors seek help for physical problems they may be experiencing, such as vaginal dryness, dyspareunia, chemically induced menopause, reduced...
Is Aspirin Protective against Colorectal Cancer?
A growing body of evidence provides biologic and clinical evidence that nonsteroidal anti-inflammatory agents are protective against colorectal cancer. “It is fascinating for me as a medical oncologist and epidemiologist to see how the worlds of colorectal cancer treatment and epidemiology are...
Successful Salvage Treatment Possible in Some Patients Who Do Not Have a Transplant in First Remission
Among 3,919 patients with acute myeloid leukemia (AML) who did not undergo transplantation in first complete remission, 1,271 relapsed and 19% were successfully treated with salvage therapy, according to an analysis of three AML trials in the United Kingdom. This percentage can be improved with a...
Bortezomib Added to Standard Induction Therapy Produced Encouraging AML Remission Rate
Adding bortezomib (Velcade) to standard daunorubicin and cytarabine induction chemotherapy for acute myeloid leukemia (AML) “resulted in an encouraging remission rate” in previously untreated older adults, according to results of Cancer and Leukemia Group B (CALGB/Alliance) study 10502. The...
Fred Hutchinson Cancer Research Center Survivorship Program to Lead New Study on Cancer In Young Adults
The Fred Hutchinson Cancer Research Center Survivorship Program and its Directors, K. Scott Baker, MD, and Karen Syrjala, PhD, have been selected to lead a nationwide study that aims to improve long-term health outcomes for cancer survivors between the ages of 18 and 39 years. Underway this spring, ...
Acts of Kindness Were Key to My Survival
Just 1 month after undergoing a mammogram that was deemed normal with some dense tissue in my left breast, my gynecologist felt a mass in that breast about the size of a cherry tomato during a routine well visit. After watching the lump for a month to see if it was cyclical, she sent me for another ...
American Association for Cancer Research Honors Award Recipients at Annual Meeting
The American Association for Cancer Research (AACR) named the following as recipients of awards at the recent Annual Meeting. Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research Hagop Kantarjian, MD, Chair and Professor in The University of Texas MD Anderson...
Expect Questions from Younger Women about Breast Cancer
“SEER data showed a small but statistically significant increase in the incidence of breast cancer with distant involvement for women aged 25 to 39 years,” concluded a study published in the Journal of the American Medical Association.1 “The trajectory of the incidence trend predicts that an...
Increase in Advanced Breast Cancer among Younger Women Is Small but Significant, and Trend Is Likely to Continue
The incidence of advanced breast cancer among women aged 25 to 39 years increased by an average of 2.07% per year from 1976 to 2009 and the trend seems likely to continue, according to an analysis of data for 936,497 women diagnosed with malignant breast cancer. The small but statistically...
Rally for Medical Research Draws Thousands in Person and on Social Media
In estimated 10,000 demonstrators filled the streets in front of Washington, DC’s historic Carnegie Library on April 8 to protest budget cuts at the National Institutes of Health. The Rally for Medical Research was held to “emphasize to our policymakers that medical research must become a national...
From One to Many, Here and Around the World
The Conquer Cancer Foundation Grants and Awards Program has grown tremendously in 30 years, from supporting just one researcher in the United States to thousands working around the world. These investigators are performing breakthrough research in all aspects of cancer and making discoveries that...
ASCO's Pre-Annual Meeting Seminar Series to Offer a New, Fourth Focus: Genetics and Genomics
ASCO’s pre–Annual Meeting seminar series continues this year, offering intimate, discussion-based seminars just before the start of the Annual Meeting in late May. The seminars are an excellent educational opportunity for health providers who are attending the Annual Meeting but would like to drill ...
A Promising New Agent's Road to Approval in CLL Raises Questions, Stirs Controversy
Early trial results in single-agent therapy with the oral Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib have produced excellent responses in patients with chronic lymphocytic leukemia (CLL). Moreover, ibrutinib is extremely well tolerated, allowing patients to remain on trial and receive the...
Access to Care: Who Gets Referred to a Medical Oncologist and/or Another Cancer Specialist and Who Receives Treatment for Advanced Cancer?
What factors determine who is referred to a medical oncologist and receives treatment for advanced cancers? Several articles in the Journal of Oncology Practice suggest that factors influencing referral and treatment go beyond the patient’s medical condition and preference and include such details...
More Recreational Physical Activity Associated with Reduced All-cause Mortality in Patients with Colorectal Cancer
In a study recently reported in Journal of Clinical Oncology, Peter T. Campbell, PhD, and colleagues from the Epidemiology Research Program of the American Cancer Society, Atlanta, found that more recreational physical activity before and after a diagnosis of colorectal cancer was associated with...
SIDEBAR: Prolonged VEGF Inhibition
The so-called TML (Treatment across Multiple Lines) study reported by Bennouna and colleagues investigated the efficacy of bevacizumab (Avastin) beyond progression from first- to second-line therapy in advanced colorectal cancer, a strategy that was supported by data from observational cohort...
Benefit of Continued Antiangiogenic Treatment with Bevacizumab after Progression in Metastatic Colorectal Cancer
As reported recently in Lancet Oncology by Jaafar Bennouna, MD, of Institut de Cancérologie de l’Ouest, Nantes, France, and colleagues, the phase III ML18147 trial showed a survival benefit with continued bevacizumab (Avastin) treatment after first progression in metastatic colorectal cancer.1 The...
Sentinel Node Biopsy in Melanoma: Essential or Optional?
Is sentinel node biopsy in melanoma an essential component of care? Despite a large multinational trial and recently published or updated guidelines, the question is still a thorny one according to experts who debated the issue at the recent meeting of the Society of Surgical Oncology in...
CancerLinQ Prototype Demonstrates Use of Big Data in Clinical Care
ASCO has unveiled the prototype of a computer system that will allow oncologists, from their desks, to leverage “big data” to measure the quality of care that their practices provide. The prototype is a major step in the development of CancerLinQ, a system that will eventually allow millions of...
SIDEBAR: The Ethical Imperative of Clinical Equipoise
In her editorial about the RESONATE trial (page 1), Dr. O’Brien raises the issue of equipoise in this phase III clinical trial that compares the efficacy of ibrutinib and ofatumumab (Arzerra) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are not appropriate...
Ibrutinib CLL Trial: Where Is the Equipoise?
The RESONATE trial is randomly assigning patients with refractory or relapsed CLL to either ofatumumab (Arzerra) or the investigational oral agent ibrutinib. Ofatumumab is an anti-CD20 monoclonal antibody like rituximab (Rituxan), but is more potent as a single agent. It was approved for refractory ...
Does Every Melanoma Patient with a Positive Sentinel Node Need More Lymph Nodes Removed?
When sentinel node biopsy was shown to predict whether early melanoma had spread to regional lymph nodes, it revolutionized care. Before that, dissection of all regional lymph nodes was the norm for most patients. After that, the standard of care became a sentinel node biopsy and then—only if the...
Emil 'Tom' Frei III, MD, Trailblazer in the Development of Combination Chemotherapy, Dies at 89
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
Saul N. Weingart, MD, PhD, Named New Chief Medical Officer of Tufts Medical Center
Tufts Medical Center has appointed Saul N. Weingart, MD, PhD, of Newton, Massachusetts as its next Chief Medical Officer. Dr. Weingart is currently serving as Vice President for Quality Improvement and Patient Safety at Dana-Farber Cancer Institute in Boston. He is a nationally renowned leader in...
High Levels of Psychological Distress Are Common among Parents of Children with Advanced Cancer
High to severe levels of psychological distress are common among parents of children with advanced cancer, according to a study conducted at three children’s hospitals—Boston Children’s Hospital, Children’s Hospital of Philadelphia, and Seattle Children’s Hospital. The cohort study was embedded in...
Ruxolitinib Results in Clinically Meaningful Symptom Improvement
Patients with myelofibrosis who received ruxolitinib (Jakafi) therapy experienced “meaningful reductions in symptom burden” and improvements in quality of life in a double-blind, placebo-controlled phase III trial published in the Journal of Clinical Oncology. The COMFORT-I (Controlled...
Cisplatin and Radiotherapy Linked to Increased Renal Cancer Risk in Childhood Cancer Survivors
Survivors of childhood cancer have an increased risk of subsequent renal cancers compared to the general population, researchers reported in the Journal of the National Cancer Institute. The risk is particularly high among survivors of neuroblastoma and those who have had irradiation involving the...
Higher Prediagnosis Body Mass Index Raises Mortality Risk in Endometrial Cancer
Higher prediagnosis body mass index (BMI) increases risk of overall and disease-specific mortality among women diagnosed with endometrial cancer, suggested a study published in the Journal of the National Cancer Institute. Physical activity was associated with reduced risk of all-cause, but not...
Expect Questions about Experience and Outcomes
“Patients are becoming more sophisticated in their ability and willingness to interrogate the health-care system about their care,” according to Robert E. Bristow, MD, MBA, lead author of the study finding that many women with ovarian cancer are not receiving care consistent with National...
Most Women with Ovarian Cancer Do Not Get Guideline-specified Treatment Linked to Survival Benefits
Most women with ovarian cancer are not receiving adequate treatment, as specified in National Comprehensive Cancer Network (NCCN) Guidelines,1 and as a result are being deprived of the survival benefits correlated with guideline-recommended treatment, according to a study presented at the Society...
Obese Men with Benign Biopsy at High Risk for Prostate Cancer
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to data published recently in Cancer Epidemiology, Biomarkers & Prevention.1 “Our study ...
Mammography Screening and DCIS
I would like to suggest that ASCO take a proactive approach to the treatment of ductal carcinoma in situ (DCIS) and the problem it presents to the oncology community. There has been and continues to be heated debate around the value of mammography screening because of “overdiagnosis,” which in my...
The ASCO Post Up Close: Our Reporters and Contributors
About the Writers Charlotte Bath has been writing about cancer and related fields of medicine since serving as Public Information Director of the American Cancer Society, Long Island Division, from 1975 to 1979. She subsequently worked as a writer for Memorial Sloan-Kettering Cancer Center and...
Living with the Fear of Cancer
After a friend was diagnosed with breast cancer, I became so worried it would happen to me, I decided to perform regular breast self-exams so I could familiarize myself with the normal feel of my breasts, and quickly spot any changes. My friend’s diagnosis scared me, and that fear probably saved my ...
Dr. Bernard Fisher's Breast Cancer Research Left a Lasting Legacy of Improved Therapeutic Efficacy and Survival
Bernard Fisher, MD, is recognized today for his groundbreaking research in breast cancer, which ultimately ended the standard practice of performing the Halsted radical mastectomy, a treatment that had been in place for more than 75 years. His laboratory and clinical investigations led to more...
Robert S. Miller, MD, FACP, Appointed Editor-in-Chief of ASCO's Patient Information Website, Cancer.Net
Robert S. Miller, MD, FACP, has been appointed Editor-in-Chief of ASCO’s patient information website, Cancer.Net. Dr. Miller will assume this role at the 2013 ASCO Annual Meeting in Chicago on June 1, and succeeds Diane Blum, MSW, Chief Executive Officer for the Lymphoma Research Foundation, who...
Drug Approvals in Acute Myeloid Leukemia: Can We Do Better?
Forty years ago, President Richard Nixon announced a “war on cancer.” Some of that war’s first battles were won in the field of acute myeloid leukemia (AML) with two agents, cytarabine and daunorubicin, receiving U.S. Food and Drug Administration (FDA) approval based on their ability to produce...
Focus on Alaska's Denali Oncology Group
Located in Anchorage, Alaska, the Denali Oncology Group faces the dual challenge of serving a diverse and large population of more than 731,000 spread across a vast state of 586,000 square miles, with just 20 medical oncologists and 5 radiation oncologists located mainly in Alaska’s two biggest...
Memorial Sloan-Kettering Cancer Center Announces New Appointments
Memorial Sloan-Kettering Cancer Center in New York recently announced the following appointments: Chief of Lymphoma Anas Younes, MD, has been named Chief of the Lymphoma Service in the Division of Hematologic Oncology, Department of Medicine. An internationally recognized medical oncologist with...
Lynch Syndrome: A Multitude of Predispositions
The current uncertainty regarding the relative frequencies of cancers of various anatomic sites in Lynch syndrome poses a difficulty in commenting on the syndrome’s overall cancer spectrum. It is even more vexing to address the order in which these cancers are prone to occur. What we do know is...
Women with Lynch Syndrome and Endometrial Cancer Are at Increased Risk of Other Cancers
Lynch syndrome is an autosomal dominantly inherited disorder due to germline mutations in DNA mismatch repair genes. Mismatch repair mutation carriers are at increased risk of several cancers, with endometrial cancer being one of the most commonly diagnosed cancers in women with Lynch syndrome. In...
